journal article·2024-06-06Open access

Risk of Radiation-Induced Second Primary Cancers and Cardiotoxicity following Therapeutic Irradiation for Thymoma with Photon Beams: A Treatment Planning Study

Michalis Mazonakis, Stefanos Kachris, Maria Tolia, John Damilakis

Applied Sciences· Volume 14· Issue 11

Abstract

This study compared the risks for developing second primary cancers and cardiotoxicity following radiotherapy for thymoma. Three different 3D-CRT, IMRT, and VMAT plans were generated with 6 MV photons for 12 females with thymoma. Dose-volume histogram data were employed to estimate the second cancer risks using a mechanistic non-linear model. The radiation doses to the heart and cardiac substructures were combined with linear models to assess the probability of cardiotoxicity. The mean lifetime risk for lung, esophageal, thyroid, left breast, and right breast cancer induction was 4.34–4.49%, 0.30–0.31%, 0.05–0.07%, 2.06–2.30%, and 2.04–2.34%, respectively, depending upon the radiotherapy technique. The relative risk for major cardiac events, including myocardial infarction, coronary revascularization, and death, was 1.43–1.55, whereas that for chronic heart failure was 1.20–1.29. The IMRT and VMAT significantly reduced the risk for cardiotoxicity with respect to 3D-CRT (p ≤ 0.023). Small but significant reductions were observed for most organ-specific cancer risks with IMRT compared to conformal treatment (p ≤ 0.008). Similar decreases were detected only for esophageal and thyroid cancer with VMAT (p ≤ 0.033). No difference was found in the probability for radiation-induced lung cancer with the three techniques (p ≥ 0.06). Healthcare professionals may use these data to select the appropriate radiotherapy technique and restrict the risk of late effects.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Myasthenia Gravis and Thymoma · Radiation Dose and Imaging · Cancer-related cognitive impairment studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Physics, Faculty of Medicine, University of Crete, 71003 Iraklion, Greece

Department of Radiation Oncology, University Hospital of Iraklion, 71110 Iraklion, Greece

References (36)

Show source-provided references
1. Thymic epithelial tumours: A population-based study of the incidence, diagnostic procedures and therapy10.1016/j.ejca.2007.11.004 ↗
2. Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999–201910.3389/fonc.2023.1308989 ↗
3. Maniar, R., and Loehrer, P.J. (2024). What have we learned from molecularly informed clinical trials on thymomas and thymic carcinomas—Current status and future directions?. Cancers, 16.10.3390/cancers16020416 ↗
4. National Comprehensive Cancer Network (2024, January 28). NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas, Version 1. Available online: www.nccn.org.
5. The role of postoperative radiotherapy for thymomas: A multicentric retrospective evaluation from three Italian centers and review of the literature10.21037/jtd-2019-thym-09 ↗
6. National Research Council (2006). Health Risks from Exposure to Low Levels of Ionizing Radiation, BEIR VII-Phase 2, National Academies Press.
7. Radiation therapy in the thoracic region: Radio-induced cardiovascular disease, cardiac delineation and sparing, cardiac dose constraints, and cardiac implantable electronic devices10.1016/j.canrad.2023.06.027 ↗
8. Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma10.1007/s00432-020-03281-z ↗
9. Konig, L., Horner-Rieber, J., Forsthoefel, M., Haering, P., Meixner, E., Eichkorn, T., Kramer, A., Mielke, T., Tonndorf-Martini, E., and Haefner, M.F. (2022). Secondary malignancy risk following proton vs. X-ray radiotherapy of thymic epithelial tumors: A comparative modeling study of thoracic organ-specific cancer risk. Cancers, 14.10.3390/cancers14102409 ↗
10. Lidestahl, A., Johansson, G., Siegbahn, A., and Lind, P.A. (2021). Estimated risk of radiation-induced cancer after thymoma treatments with proton- or X-ray beams. Cancers, 13.10.3390/cancers13205153 ↗
11. Predicted rate of secondary malignancies following adjuvant proton versus photon radiation therapy for thymoma10.1016/j.ijrobp.2017.04.022 ↗
12. Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies10.1080/0284186X.2017.1302097 ↗
13. Patients’ needs in proton therapy: A survey among ten European facilities
14. Assessing equity of access to proton beam therapy: A literature review10.1016/j.clon.2023.05.014 ↗
15. A cardiac contouring atlas for radiotherapy10.1016/j.radonc.2017.01.008 ↗
16. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma10.1080/0284186X.2018.1502467 ↗
17. Dosimetric analysis of postoperative radiotherapy for thymoma10.1016/j.canrad.2021.07.037 ↗
18. Halperin, E.C., Wazer, D.E., Perez, C.A., and Brady, L.A. (2019). Principles and Practice of Radiation Oncology, Wolter Kluwer. [7th ed.].
19. Models for the risk of secondary cancers from radiation therapy10.1016/j.ejmp.2017.02.015 ↗
20. Intensity modulated radiation therapy, protons, and the risk of second cancers10.1016/j.ijrobp.2006.01.027 ↗
21. Out-of-field organ doses and associated risk of cancer development following radiation therapy with photons10.1016/j.ejmp.2021.09.005 ↗
22. Schneider, U., Sumila, M., and Robotka, J. (2011). Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor. Biol. Med. Model., 8.10.1186/1742-4682-8-27 ↗
23. United States life tables, 2017
24. Involved node, site, field and residual volume radiotherapy for lymphoma: A comparison of organ at risk dosimetry and second malignancy risks10.1016/j.clon.2015.03.005 ↗
25. A software tool for organ-specific second cancer risk assessment from exposure to therapeutic doses10.5603/RPOR.a2022.0014 ↗
26. Risk of ischemic heart disease in women after radiotherapy for breast cancer10.1056/NEJMoa1209825 ↗
27. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines10.1182/blood-2016-09-740332 ↗
28. A planning strategy may reduce the risk of heart diseases and radiation pneumonia: Avoiding the specific heart substructures10.1002/acm2.14119 ↗
29. Howlader, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute.
30. NTCP calculations of five different irradiation techniques for the reatment of thymoma10.3390/curroncol30080561 ↗
31. Mazonakis, M., Tzanis, E., Lyraraki, E., and Damilakis, J. (2022). Automatic radiobiological comparison of radiation therapy plans: An application to gastric cancer. Cancers, 14.10.3390/cancers14246098 ↗
32. The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques10.1016/j.radonc.2020.05.035 ↗
33. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas10.1118/1.4944422 ↗
34. Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin Lymphoma in female patients10.1080/0284186X.2021.1986230 ↗
35. Radiation-induced secondary malignancies: A review article10.3857/roj.2018.00290 ↗
36. Martin, C.J., Gros, S., Kron, T., Wood, T.J., Vassileva, J., Small, W., and Min, U.N. (2023). Factors affecting implementation of radiological protection aspects of imaging in radiotherapy. Appl. Sci., 13.10.3390/app13031533 ↗